Prevalence of anti-ulcer drug use in a Chinese cohort

World Journal of Gastroenterology

Volumn 9, Issue 6, 2003, Pages 1365-1369

  Chen, Tzeng Ji ^a,b   Chou, Li Fang ^c   Hwang, Shinn Jang ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL CHENGCHI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIULCER AGENT; BISMUTH CITRATE; CARBENOXOLONE; CETRAXATE; CIMETIDINE; FAMOTIDINE; GEFARNATE; GENERIC DRUG; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; MISOPROSTOL; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PIRENZEPINE; PROGLUMIDE; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; ROXATIDINE; SUCRALFATE; UROGASTRONE;

AGE; AMBULATORY CARE; ARTICLE; CALCULATION; CHINA; COHORT ANALYSIS; DATA BASE; DRUG USE; EPIDEMIOLOGICAL DATA; GASTROESOPHAGEAL REFLUX; HEALTH INSURANCE; HEALTH PROGRAM; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; LOW DRUG DOSE; PEPTIC ULCER; PRESCRIPTION; PREVALENCE; TAIWAN;

EID: 0038383782     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i6.1365     Document Type: Article

References (27)

1. 2-receptor antagonists to Scandinavia: Effects of expert's opinions. Scand J Gastroenterol 1998; 33: 224-230
2. Soll AH. Medical treatment of peptic ulcer disease: Practice guidelines. JAMA 1996; 275: 622-629
3. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 1998; 93: 2330-2338
4. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999; 94: 1434-1442
5. Andersen IB, Bonnevie O, Jørgensen T, Sørensen TIA. Time trends for peptic ulcer disease in Denmark, 1981-1993: Analysis of hospitalization register and mortality data. Scand J Gastroenterol 1998; 33: 260-266
6. Thors H, Svanes C, Thjodleifsson B. Trends in peptic ulcer morbidity and mortality in Iceland. J Clin Epidemiol 2002; 55: 681-686
7. McGavock H, Webb CH, Johnston GD, Milligan E. Market penetration of new drugs in one United Kingdom region: Implications for general practitioners and administrators. BMJ 1993; 307: 1118-1120
8. McManuy P, Marley J, Birkett DJ, Lindner J. Compliance with restrictions on the subsidized use of proton pump inhibitors in Australia. Br J Clin Pharmacol 1998; 46: 409-411
9. Cromwell DM, Bass EB, Steinberg EP, Yasui Y, Ravich WJ, Hendrix TR, McLeod SF, Moore RD. Can restrictions on reimbursement for anti-ulcer drugs decrease Medicaid pharmacy costs without increasing hospitalizations? Health Serv Res 1999; 33: 1593-1610
10. O'Connor JB, Provenzale D, Brazer S. Economic considerations in the treatment of gastroesophageal reflux disease: A review. Am J Gastroenterol 2000; 95: 3356-3364
11. Lucas LM, Gerrity MS, Anderson T. A practice-based approach for converting from proton pump inhibitors to less costly therapy. Eff Clin Pract 2001; 4: 263-270
12. Thors H, Sigurdsson H, Oddsson E, Thjodleifsson B. Survey of prescriptions for peptic ulcer drugs (ACT class A02B) in Iceland. Scand J Gastroenterol 1994; 29: 988-994
13. Roberts SJ, Bateman DN. Prescribing of antacids and ulcer-healing drugs in primary care in the north of England. Aliment Pharmacol Ther 1995; 9: 137-143
14. Goudie BM, McKenzie PE, Cipriano J, Griffin EM, Murray FE. Repeat prescribing of ulcer healing drugs in general practice - Prevalence and underlying diagnosis. Aliment Pharmacol Ther 1996; 10: 147-150
15. Moride Y, Melnychuk D, Monette J, Abenhaim L. Determinants of initiation and suboptimal use of anti-ulcer medication: A study of the Quebec older population. J Am Geriatr Soc 1997; 45: 853-856
16. Morales Suárez-Varela MM, Pérez-Benajas MA, Girbes Pelechano VJ, Llopis-González A. Antacid (A02A) and antiulcer (A02B) drug prescription patterns: Predicting factors, dosage and treatment duration. Eur J Epidemiol 1998; 14: 363-372
17. Bashford JNR, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link morbidity and prescribing in the General Practice Research Database. BMJ 1998; 317: 452-456
18. 2-receptor antagonists and proton pump inhibitors in primary care. Aliment Pharmacol Ther 1998; 12: 797-805
19. Prach AT, McGilchrist MM, Murray FE, Johnston DA, MacDonald TM. Prescription of acid-suppressing drugs in relation to endoscopic diagnosis: A record-linkage study. Aliment Pharmacol Ther 1999; 13: 397-405
20. Boutet R, Wilcock M, MacKenzie I. Survey on repeat prescribing for acid suppression drugs in primary care in Cornwall and the Isles of Scilly. Aliment Pharmacol Ther 1999; 13: 813-817
21. Jones MI, Greenfield SH, Jowett S, Bradley CP, Seal R. Proton pump inhibitors: A study of GPs' prescribing. Fam Pract 2001; 18: 333-338
22. Bureau of National Health Insurance. 2001 National Health Insurance Annual Statistical Report. Taipei: Bureau of National Health Insurance 2002
23. Liu JY, Chen TJ, Hwang SJ. Concomitant prescription of non-steroidal anti-inflammatory drugs and antacids in the outpatient setting of a medical center in Taiwan: A prescription database study. Eur J Clin Pharmacol 2001; 57: 505-508
24. Guidelines for ATC Classification and DDD Assignment, 3rd ed. Oslo: WHO Collaborating Centre for Drug Statistics Methodology 2000
25. OECD Health Data 2001. Paris: OECD (Organisation for Economic Co-operation and Development) 2001
26. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000; 25: 333-340
27. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol 2000; 95: 3118-3122